Skip to main content
EU to review expanded use of Clovis' Rubraca

The application for the use of Clovis Oncology's PARP inhibitor Rubraca, or rucaparib, as a maintenance treatment for adults with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who exhibited at least a partial response to platinum-based chemotherapy was accepted for review by European regulators. The application was backed by data from a late-stage trial, in which the drug demonstrated significantly extended progression-free survival compared with placebo as a maintenance treatment for patients with ovarian cancer, regardless of BRCA status.

Full Story: